{"id":"W2981659669","doi":"10.1016/j.thromres.2019.09.033","title":"Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition","year":2019,"lang":"en","type":"review","venue":"Thrombosis Research","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Boehringer Ingelheim; Bayer; Pfizer","keywords":"Rivaroxaban; Aspirin; Medicine; Pharmacology; Thrombin generation; ATHEROSCLEROTIC VASCULAR DISEASE; Coronary artery disease; Thrombin; Vascular disease; Cardiology; Platelet; Internal medicine; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004813473,0.0004620814,0.002253866,0.0003270338,0.000782273,0.0001577009,0.0001967143,0.0004899238,0.00006188999],"category_scores_gemma":[0.0004633615,0.0003045131,0.005003158,0.0005513477,0.0003608089,0.0001318616,0.0001569025,0.0007339263,0.00006676721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003075511,"about_ca_system_score_gemma":0.001193923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004125714,"about_ca_topic_score_gemma":0.000003452896,"domain_scores_codex":[0.9956512,0.000738233,0.0005396266,0.0009244066,0.001493444,0.0006530659],"domain_scores_gemma":[0.996564,0.0009010386,0.0001138612,0.001325615,0.0009071965,0.0001882421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001904656,0.0001312755,9.153674e-7,0.04338391,0.01491349,0.00001037448,0.0001223929,0.00002096878,0.00001969788,0.0007689885,0.001242607,0.9391949],"study_design_scores_gemma":[0.003120189,0.0005399355,0.00003843981,0.004709329,0.005523472,0.0001056004,0.000151691,0.0001192898,0.00003093467,0.000191393,0.9851331,0.0003366734],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001442546,0.9727238,0.00516637,0.0002082627,0.0001948809,0.02115837,0.0002478297,0.00006223304,0.00009398467],"genre_scores_gemma":[0.0002349402,0.986503,0.0002284563,0.00004870647,0.001393697,0.0102294,0.0007181733,0.0001462068,0.0004973996],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9838905,"threshold_uncertainty_score":0.9999407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3453645301045887,"score_gpt":0.4302358989388002,"score_spread":0.08487136883421148,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}